

Please type a plus sign (+) inside this box.

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

**Complete if Known**

Application Number	10/087,112
Filing Date	March 1, 2002
First Named Inventor	Jin, F et al.
Group Art Unit	N/A
Examiner Name	N/A
Attorney Docket Number	PHA2001US

RECEIVED

JAN 16 2003

TECH CENTER 1600/2900

Sheet 1 of 1

**U.S. PATENT DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			
yz	AA	4,594,339		Lopez, C. et al.	06-10-1986	—
	AB	4,847,366		Yamamoto, Y. et al.	07-11-1989	—
	AC	5,212,298		Radamacher, T. W. et al.	05-18-1993	—
	AD	5,625,057		Shiragami, Hiroshi et al.	04-29-1997	—

**FOREIGN PATENT DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document DD-MM-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Office <sup>3</sup>	Number	Kind Code <sup>2</sup> (if known)				
yz	AE	EP	0 334 368		Bristol Myers Co.	27-19-1989	—	

**OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
yz	AF	COE, et al., <i>Journal of Fluorine Chemistry, Elsevier Sequoia, Lausanne, CH</i> , vol. 69, no. 1, pp. 19-24, 1994.	
	AG	CLASSON, B. et al., <i>ACTA Chem. Scand., Ser. B.</i> , B36(4), 251-3, 1982.	
	AH	MANSURI, M M et al., <i>J. of Organic Chemistry, American Chemical Society</i> , vol. 54, no. 20, 29 Sept. 1989, 1780-4785.	
	AI	OZAKI, S. et al., <i>Bull. Chem. Soc. Jpn.</i> , 50(8), 2197-8, 1977.	
	AJ	OZAKI, S. et al., <i>Nucleic Acids Symp. Ser.</i> , 9-1, 12, p. 11, table 1, 1983.	
	AK	WATANABE, K.A. et al., <i>J. Med. Chem.</i> , 23(10), 1088-94, 1980.	
	AL	VAN AERSCHOT, A. et al., <i>J. MED Chem</i> , 33(6), 1833-9, 1990.	


Examiner  
Signature*Thomas C. Huf*Date  
Considered

7/13/02

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → 

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete if Known</b>	
		Application Number	10/087,112
		Filing Date	March 1, 2002
		First Named Inventor	Jin, F et al.
		Group Art Unit	N/A
		Examiner Name	N/A
		Attorney Docket Number	08841.105031 (PHA2002US)
Sheet	2	of	3

**OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
T	BA	ABDEL-MEDIED, A. W.-S., <i>et al.</i> , <i>Synthesis</i> , 1991, 313.	
	BB	CHEN S., <i>et al.</i> "Synthesis and Biological Evaluation of a Series of 2'-Fluorinated-2',3'-Didehydro-(L)-Nucleosides." <i>Biorganic &amp; Medicinal Chemistry Letters</i> . 8:3245-3250, 1998.	
	BC	CHEN, S., <i>et al.</i> "Stereoselective Syntheses of $\beta$ -L-FD4C and $\beta$ -L-FddC." <i>J. Org. Chem.</i> 62(11):3449-3452, 1997.	
	BD	CHENG, Y., <i>et al.</i> , <i>J. Med. Chem.</i> 1996, 62, 1757-1759.	
	BE	HORWITZ, J. P., <i>et al.</i> "Nucleosides. IX. The Formation of 2',3'-Unsaturated Pyrimidine Nucleosides via a Novel $\beta$ -Elimination Reaction." <i>J. Org. Chem.</i> 31:205-211, January 1966.	
	BF	HORWITZ, J. P., <i>et al.</i> "Nucleosides. VI. The Introduction of Unsaturation into the Carbohydrate of a Pyrimidine Nucleoside via a 2,3'-Anhydro Bond." <i>J. Am. Chem. Soc.</i> 86:1896-1897, May 5, 1964.	
	BG	HORWITZ, J. P., <i>et al.</i> "Nucleosides. XI. 2',3'-Dideoxycytidine." <i>J. Org. Chem.</i> 32:817-818, March 1967.	
	BH	JAIN, T.C., <i>et al.</i> "Reactions of 2-Acyloxyisobutyryl Halides with Nucleosides. IV. A Facile Synthesis of 2',3'-Unsaturated Nucleosides Using Chromous Acetate." <i>J. Org. Chem.</i> 39(1):30-38, 1974.	
	BI	MANCHAND <i>et al.</i> "Syntheses of the Anti-AIDS Drug 2',3'-Dideoxycytidine from Cytidine." <i>J. Org. Chem.</i> 57(12):3473-3478, 1992.	
	BJ	MORIKAWA, T., <i>et al.</i> , <i>Chem. Pharm. Bull.</i> , 1992, 40, 3189	
	BK	PATRICK, T.B., <i>et al.</i> "New Fluorobutenolide Templates for Synthesis." <i>J. Org. Chem.</i> 59(5):1210-1212, 1994.	
	BL	ROBINS, M. J., <i>et al.</i> , <i>Tetrahedron Letters</i> 1984, 25, 367.	
	BM	RUSSELL, A. F., <i>et al.</i> , <i>J. Am. Chem. Soc.</i> 1973, 95, 4025.	

Examiner Signature		Date Considered	7/15/03
--------------------	---	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐


PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		<b>Complete if Known</b>		
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number	10/087,112	
		Filing Date	March 1, 2002	
		First Named Inventor	Jin, F et al.	
		Group Art Unit	N/A	
		Examiner Name	N/A	
Sheet	3	of	Attorney Docket Number	08841.105031 (PHA2002US)



OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
gm	CA	SHI, <i>et al.</i> "Synthesis and Biological Evaluation of 2',3'-Didehydro-2',3'-dideoxy-5-fluorocytidine (D4FC) Analogues: Discovery of Carbocyclic Nucleoside Triphosphates with Potent Inhibitory Activity against HIV-1 Reverse Transcriptase." <i>J. Med. Chem.</i> 42:859-867, 1999.	
	CB	SUJINO, K., <i>et al.</i> "Facile Synthesis of 2',3'-Unsaturated Nucleosides from 2-Deoxyribose." <i>Tetrahedron Letters.</i> 37(34):6133-6136, 1996	
	CC	THENAPPAN, A., <i>et al.</i> "Reduction-Olefinatation of Esters: A New and Efficient Synthesis of $\alpha,\beta$ -Unsaturated Esters." <i>J. Org. Chem.</i> 55(15):4639-4612, 1990.	
	CD	VERHEYDEN, J.P., <i>et al.</i> "2',3'-Unsaturated nucleosides." <i>Chem. Abstr.</i> 81:508(63942), 1974.	

Examiner Signature	<i>[Signature]</i>	Date Considered	7/15/02
--------------------	--------------------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.


Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐

App. for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)			<b>Complete if Known</b>	
			Application Number	10/087,112
			Filing Date	March 1, 2002
			First Named Inventor	Jin, F et al.
			Group Art Unit	N/A
			Examiner Name	N/A
			Attorney Docket Number	08841.105031 (PHA2002US)
Sheet	1	of		



U.S. PATENT DOCUMENTS						
Examiner Initials *	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			
JCM	AA	3,817,982		Verheyden <i>et al.</i>	06-18-1974	
	AB	4,900,828		Belica <i>et al.</i>	02-13-1990	
	AC	4,904,770		Starrett, Jr. <i>et al.</i>	02-27-1990	
	AD	5,130,421		Starrett, Jr. <i>et al.</i>	07-14-1992	
	AE	5,455,339		Chu	10-03-1995	
	AF	5,539,099		Skonezny <i>et al.</i>	07-23-1996	
	AG	5,561,120		Lin <i>et al.</i>	10-01-1996	
	AH	5,703,058		Schinazi <i>et al.</i>	12-30-1997	
	AI	5,905,070		Schinazi <i>et al.</i>	05-18-1999	
	AJ	6,232,300		Schinazi <i>et al.</i>	05-15-2001	

FOREIGN PATENT DOCUMENTS								
Examiner Initials *	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document DD-MM-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Office <sup>3</sup>	Number	Kind Code <sup>2</sup> (if known)				
JCM	AK	WO	99/43691	A1	Schinazi et al.	02-09-1999		
	AL	WO	96/22778	A1	Schinazi et al.	01-08-1996		
	AM	EP	0 409 227	A2	Matthes et al.	19-07-1990		

Examiner Signature		Date Considered	2/15/02
--------------------	--	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.